Background: Plants containing compounds such as the isoflavonoids, with female hormone-like effects that bind to human estrogen receptors, are known. But none has been previously shown to have corresponding male hormone-like effects that interact with the human androgen receptor. Here, we report that the tree bark (cortex) of the Gutta-Percha tree Eucommia ulmoides possesses bimodal phytoandrogenic and hormone potentiating effects by lipidic components.
Background
The androgen receptor (AR) plays a pivotal role in human (both male and female) physiology such as skeletal muscle development, bone density, fertility and sex drive [1, 2] . The α and β estrogen receptors (ERs), likewise, have fundamental impact on the sex hormone-mediated physiological milieu. Conversely, over-active sex steroid (androgen and estrogen) receptors have been linked to increased risks of hormone-sensitive tumours such as prostate and breast cancers. Availability and binding of cognate ligands to the ligand binding domain (LBD) of the sex steroid receptors are required for the proportionate expression of specific genes responsible for such sex hormone-mediated processes [3, 4] .
Vegetative foods such as the legumes, particularly soybean (Glycine max), contain phytoestrogens that modulate the transcriptional activities of the estrogen receptor isoforms, α and β. The former has been linked to the chemoprevention of specific cancers in the breast and prostate gland [5] .
Here, we report that the tree bark (cortex) of the GuttaPercha tree Eucommia ulmoides OLIVER possesses novel bimodal phytoandrogenic and synergistic augmentation of hormone-dependent receptor activity. E. ulmoides is also known variously as the Gutta Percha Tree, the Rubber Bark Tree or Du-Zhong [6, 7] . The toothed elliptic leaves and tree bark of E. ulmoides (figure 1) are used medicinally in herbal pharmacopoeias such as Kampo (traditional Japanese medicine) and Zhong-Yao (traditional Chinese medicine) for indications such as the relief of back pain, to increase stamina, to make bones and muscles 'strong' and to hasten recovery from fatigue. It is noted that these are male hormone-related pharmacological effects.
Through the combined use of varied technologiesrecombinant DNA constructs, reporter gene assays, animal studies and separation chemistry, extracts of E. ulmoides were shown for the first time, to specifically activate the tranactivational capacity of the sex steroid receptors in both in-vitro and in-vivo settings. A series of bioassayguided fractionation showed that the phytoandrogenic and hormone potentiating effects of E. ulmoides were mediated by distinct groups of phytocompounds; triterpenoids and short-chain lipids respectively.
Methods

Cell culture
The mammalian COS-7 cell line was maintained in DMEM cell culture medium with 10% fetal bovine serum (FBS) and 1% of each amino acids (glutamine, arginine and lysine). Hela cells were maintained in RPMI 1640 cell culture medium (with 10% FBS, 1% L-glutamine, 1% Llysine and 1% arginine). Both cell lines were incubated at 37°C in 5% CO 2 gaseous environment.
Transient transfection of mammalian cell lines
Mutant and wild-type (WT) chimeric constructs were transfected into Hela cells, using the lipofection technique. Both are as described in [8] . Hela cells, which are a homologous cell line, was utilised for the transactivation studies. These Hela cells were cotransfected with a luciferase reporter gene containing two AREs [p(ARE) 2 -TataLuc]. Transfected cells were exposed to androgens for 48 hr before harvesting and quantification of luciferase activity. The androgens used were testosterone and dihydrotestosterone (DHT).
Binding site of phytoandrogens
Radioligand displacement assays were carried out using tritiated testosterone to determine binding site of the phytoandrogens in E. ulmoides. The COS-7 cells were transfected with AR and then exposed to 3 nM of tritiated testosterone and the indicated amounts of DHT (nM), cortisol (nM) or ethanolic E. ulmoides (EU) extract (1 concentration factor (c.f.) = 50 ng dry weight/ml treatment medium) for 2 hr at 37°C. The treated cells were harvested and the amount of tritiated testosterone bound to AR was then measured by scintillation counting. Specific binding is expressed as percent tritium bound to AR, where 100% is the amount of specific tritiated-testosterone bound in the absence of competing cold ligand minus background (non-specific binding to substrate and proteins). Each data point, the mean of quadruplicates, represents the amount of radiolabelled testosterone specifically bound on exposure to indicated doses of DHT, ethanolic EU extract or cortisol.
Luciferase assay
Luciferase assay was performed with the TD-20/20 Luminometer, following the instructions provided by the manufacturer (Promega, USA). Briefly, the transfected cells were lysed in 1× Reporter Lysis Buffer (RLB). The cell lysate was mixed with Luciferase Assay Substrate immediately before measuring. The luciferase activity was measured in relative light units (RLU).
Plant material
The dried cortex of Eucommia ulmoides OLIVER was purchased from the local wholesaler dealing exclusively in Chinese medicinal herbs. Dr Ruth Kiew, Keeper of Herbarium & Library, National Parks Board, Singapore, authenticated the plant material. A voucher specimen (BT-4) was deposited with the Singapore Botanic Gardens Herbarium.
Processed bark (cortex) from the evergreen tree Eucommia ulmoides Figure 1 Processed bark (cortex) from the evergreen tree Eucommia ulmoides. Originating from temperate regions of China, botanical parts of E. ulmoides such as the leaves and bark are used medicinally in the Chinese and Japanese Pharmacopia. Note the silvery threads of resin (Gutta Percha) in between the sliced portion of the specimen (green arrow).
Extractions
Dried cortical barks of E. ulmoides were washed with deionised water to remove contaminants. In each batch extraction, damp E. ulmoides barks were then macerated using a commercial grinder (Bosch, Germany). The resulting cortical mash was then blended with 100% ethanol solvent. Using the soak method, the blended ethanolic mash (100 g/1L) was incubated in a shaken (25 r.p.m.) water bath (Buchi Labortechnik AG, Switzerland) for 12 hr at 40°C to allow the active compounds to dissolve into the solvent system. After 12 hr, the menstrum was decanted and filtered through Whatman No.1 using a Buchner funnel in vacuo. The resulting filtrate was concentrated by evaporation under vacuum at 40°C, using a rotatory evaporator (Buchi Labortechnik AG, Switzerland). The extraction procedure was repeated 8 to 10 times until the fibrous residue was exhausted. The menstrums collected from each sequential re-extraction were concentrated and blended into a semi-solid paste. This paste was then aliquoted and resuspended in pure ethanol to obtain stock solutions (50 mg/ml) of tertiary crude extracts for downstream experimental work.
Animal housing
Male juvenile (prepubertal) WISTAR rats weighing between 48-64 g (average weight 53 g) were obtained from the Laboratory Animal Centre, National University of Singapore. The animals were fed on commercial pelleted chow and water was given ad libitum. The rats were housed individually in wide-bottomed Perspex cages. The light cycle was diurnal with 12 hr daylight. The animals were treated in accordance with the "guidelines for the care and use of laboratory animals for scientific purposes" issued by the local authority.
Animal studies
To establish the dose response relationship between intramuscular (IM) testosterone (Sustanon 5000) injections and ventral prostate weight (as a measure of prostate development), prepubertal male WISTAR rats (2 weeks old) were given IM testosterone injections of 500 µg, 2500 µg and 5000 µg while control animals were given IM injections of vehicle (olive oil) only. After 5 days, the WIS-TAR rats were sacrificed by decapitation. The abdominal flap of each rat was dissected to recover the prostate gland. The ventral prostate gland was removed and the wet weight determined. Androgen-mediated prostatic growth was expressed as the weight of the ventral prostate gland normalized to 100 g body weight of the individual rats.
To study the androgenic effect of oral E. ulmoides liquid formulation on ventral prostate growth, prepubertal male WISTAR rats were administered E. ulmoides extracts via gavaging with doses of 1 mg, 5 mg, 10 mg and 50 mg in aliquots of 1 ml vehicle (25% hydroethanolic solution).
Gavaging (gastric intubation) were carried out with gauge 18 feeding needle. Negative control animals were given oral doses of vehicle (25% hydroethanolic solution) only.
To test the potentiating effect of E. ulmoides extract on testosterone-mediated prostatic growth, prepubertal male WISTAR rats were given 5000 µg IM testosterone injections in conjunction with 50 mg of E. ulmoides extract by oral gavage. Baseline control animals were given IM injections of 5000 µg IM testosterone injections alone. Negative control animals were given IM injections of olive oil plus concurrent oral gavaging with 25% hydroethanolic solution.
Fractionations
Semi-preparative open column chromatography was carried out using diol stationary phase as previously described [10] . The chromatographic column with the E. ulmoides extract loaded on top was influxed with 50 ml of each mobile phase in increasing order of polaritydichloromethane (DCM), ethyl acetate (EA), ethanol (EtOH) and water (H 2 O). The mobile phases eluting from the chromatographic column were collected sequentially into individual fractions -fraction A, fraction B, fraction C and fraction D. These fractions were dried in a rotary evaporator at 40°C and resuspended in ethanol for bioassays.
For solid phase extraction (SPE), the SPE C-18 cartridge was flushed with ethanol to activate the C-18 hydrocarbon moieties. This was followed by water to displace the ethanol phase and equilibrate the solid phase in an aqueous environment. Using SPE method described in Ong [10] , fraction A was further resolved into four purer fractions AA, AB, AC and AD. Fraction AB with dominant phytoandrogenic activity was subsequently rechromatographed in C-18 matrix using high performance liquid chromatography (HPLC) to obtain a phytoandrogenic fraction (AB-P1) of even greater purity. AB-P1 fraction was subjected to thin layer chromatography (TLC) and a phytoandrogenic triterpenoid fraction TLC4-5 was recovered for molecular mass measurement using electron spray ionization-mass spectroscopy (ESI-MS). The TLC chromatogram of fraction AB-P1 was subjected to vanillin-sulphuric acid visualization reaction to detect presence of triterpenoids by spraying 5% ethanolic sulphuric acid. This was followed by 1% ethanolic vanillin. Colorimetric development was completed by heating the treated TLC plate at 120°C for 15 min in a thermostat oven.
Fraction C was similarly subjected to SPE using C-18 SPE cartridge and sequential fractions recovered were fractions CA and CB. The recovered fraction CB was subjected to 1 H NMR and GC-MS [10] . The overall scheme, from raw herb to confirmatory bioassays, is detailed in figure 2. Figure 2 Schematics of research process flow. E. ulmoides cortex was macerated and crude extracts obtained using solvents. These solvents were dichloromethane (DCM), ethyl acetate (EA), ethanol (EtOH) and water (H 2 O). The crude extracts were subjected to steroidogenic reporter gene and binding assays. Bioactive fractions were subsequently obtained through bioassay-guided fractionations using column chromatography, thin layer chromatography and high performance liquid chromatography (HPLC). Pharmacologically active phytocompounds purified from the bioactive fractions were identified through spectroscopic and nuclear magnetic resonance (NMR) studies. Confirmatory reporter gene assays were then carried out using pure compounds to reproduce steroidogenic effects. 
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Statistical analyses
All in-vitro reporter gene results were expressed as means ± SE from triplicate assays. Results of the radioligand displacement assays were expressed as means ± SE from quadruplicate assays. One-way ANOVA analyses were carried out to assess statistical significance for in-vivo animal experiments. Differences with p-value < 0.001 were considered statistically significant.
Results and discussion
In Luc reporter gene bioassays, E. ulmoides cortical extract demonstrated androgenic and estrogenic activities by weakly activating AR and ER transactivational function in a dose-dependent manner ( figures 3 and 4) . Highly specific radioisotopic ligand displacement bioassay showed that phytocompounds in the E. ulmoides extract were able to compete with and displace bound 3 H-labelled testosterone from the AR ligand binding domain ( figure 5 ). Subsequent bioassay-guided purification of the androgenic extract using chromatographic and ESI-MS techniques revealed that this phytoandrogenic activity was being mediated by triterpenoids, which differs from the phytoestrogenic effect exerted by isoflavonoids [5] (figures 6 and 7).
Remarkably, combination of DHT and the E. ulmoides extract in the presence of the AR led to increases in ARmediated reporter gene expression ranging from 112% to 204%, even at saturating levels of DHT ( figure 8 ). This potentiating effect was a tripartite synergism between the Radioligand displacement assay of E. ulmoides (EU) extract 
C on c e ntr a tion of e th a n olic E U e x tr a c t (c f* ), D H T (n M ) a n d C or tis ol (n M ) Percentage of tritiated testosterone remaining
E th a n olic E U extra ct (cf*) (1 cf= 5 0 n g d ry w eig h t/m l trea tm en t m ed iu m ) Figure 3 Phytoandrogenicity of E. ulmoides (EU) extract. The dose response curve of an E. ulmoides extract with concentrations ranging from 0.25 ng/ml treatment medium to 50 ng/ml treatment medium. Hela cells transiently expressing androgen receptor (AR) in the presence of AR-responsive luciferase reporter gene (Luc) were exposed to increasing doses of the extract. Comparatively, testosterone (1 nM) has 100-fold Luc activity relative to the maximal E. ulmoides 6.4-fold Luc activity. Data are mean ± SE of three replicates. Ethanolic EU extract (ng/ml treatment medium)
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Phytoandrogenicity of E. ulmoides (EU) extract
Phytoestrogenicity of E ulmoides (EU) extract AR protein, its cognate steroidal ligand and E. ulmoides's extract. This is highly unusual as normally, androgenmediated AR transcriptional capacity, akin to all liganddependent steroid receptors, plateaus at saturating doses of its cognate ligand. A similar synergistic effect was observed when E. ulmoides extract was tested in combination with estradiol in the presence of the estrogen receptor (ER) α (figure 9).
To confirm the specificity of these agonistic and synergistic interactions between the sex steroid receptors and E. ulmoides cortical extract, the progesterone (PR) and glucocorticoid (GR) receptors (which belong to the same superfamily of steroid receptors) were also subjected to the same series of reporter gene bioassays (data not shown). The cortical extract did not exert any activating effects, alone or in combination with progesterone and cortisol on the PR and GR respectively. This validates the specificity of E. ulmoides's sex steroidogenic effects on the holoandrogen and estrogen receptors.
In-vivo animal studies were then carried out to investigate the androgenic and hormone potentiating effects of E. ulmoides extract when it is administered orally. At baseline (without testosterone), the mean ventral prostate weight of the male Wistar rats was 45 mg/100 g body weight.
With a saturating dose of 5000 µg IM testosterone injection, the androgen-mediated ventral prostate growth steadied at 85 mg prostate weight/100 g body weight; oneway ANOVA showing statistically insignificant difference (p-value = 0.0562) (figure 10). Administration of E. ulmoides oral formulations at dry weight doses of 1 mg, 5 mg, 10 mg and 50 mg (n = 5 for each dosage) similarly brought about a statistically insignificant increase over baseline (p-value = 0.9319) at the maximum dose of 50 mg ( figure 11 ).
However, a combined administration of 5000 µg IM testosterone injection and E. ulmoides by oral gavaging (N = 15) augmented androgen-mediated ventral prostate growth ( figure 12) . When an oral dose of 50 mg E. ulmoides extract was co-administered together with 5000 µg of IM testosterone (n = 5 for each combination treatment), the mean ventral prostate weight increased to 93 mg/100 g body weight, demonstrating a highly significant δ difference over baseline of 53 mg/100 g body weight (p-value < 0.001). The outcome of these animal studies further indicates that E. ulmoides potentiates the effect of testosterone on the androgen receptor (figure 12).
Subsequent 1 H NMR and GC analyses of active fraction CB showed the major presence of the 8-carbon polysaturated fatty acid, caprylic acid, along with other lipids (figure 13 and table 1 ). Bioassays using pure caprylic acid and other polysaturated fatty acids (PFAs) correlated with the augmenting effect of E. ulmoides on the AR (figure 14) in varying degrees. Ethanolic extract of coconut (Cocos nucifera) flesh, rich in C-8 caprylic acid and other polysaturated fatty acids [11] , replicated the hormone potentiating effect of both E. ulmoides extract and pure caprylic acid in AR bioassays (data not shown).
Okadaic acid, a known phosphorylation promoter, is able to strongly augment androgen-dependent AR activity [12] . Interestingly, fatty acids can also promote phosphorylation. One instance is oleic acid, a C-18 cis-monosaturated fatty acid [13] . It is possible that AR and ER augmentation by both E. ulmoides extract and caprylic acid arise from a common tripartite synergism between the steroid receptors, sex steroids and fats, based on a phosphorylation mechanism.
Our studies suggest intrinsic hormone potentiating effect in PFAs per se; in addition to the calorific and structural roles that have previously been identified (for e.g. cell membrane components or structural precursors of proinflammatory cytokines). The tripartite synergism demonstrated in this study may also be helpful in clarifying the known epidemiological link between high dietary saturated fat intake (rich in PFAs), obesity and increased risks TLC silica fractionation of fraction AB-P1 and triterpenoid detection of hormone-related diseases such as prostate or breast cancer [14] .
Conclusion
The novel discoveries reported in this study add phytoandrogens and lipidic augmenters to the emerging list of hormomimetics (such as phytoestrogens) known to exist in plants. Pharmaceutical utility of lipidic augmenters in the treatment of hypogonadal conditions such as menopause or andropause could be exploited based on this mechanism of tripartite synergism. The link between excess dietary lipids, hyperandrogenism and hormonerelated disorders should also be further explored in the light of these findings.
In-vivo E. ulmoides (EU) extract and ventral prostate growth in prepubertal male WISTAR rats Figure 11 In-vivo E. ulmoides (EU) extract and ventral prostate growth in prepubertal male WISTAR rats. The androgenic effect of oral E. ulmoides liquid formulation on ventral prostate growth. Prepubertal male WISTAR rats were administered ethanolic E. ulmoides (EU) extracts via gavaging with doses of 1 mg, 5 mg, 10 mg and 50 mg. Control animals were given oral doses of vehicle (ethanolic water) only. Prostatic growth is expressed as the weight of the ventral prostate gland normalized to 100 g body weight of the individual rats. Each data point is mean ± SE of five animals' ventral prostate weights. Supra-hormonal properties of E ulmoides (EU) extract on estrogen receptor and estradiol Figure 9 Supra-hormonal properties of E ulmoides (EU) extract on estrogen receptor and estradiol. The augmenting effect of a fixed dose of E ulmoides (EU) extract on ER. Cells were exposed to increasing doses of estradiol, with or without, 50 ng/mL treatment medium of the ethanolic E ulmoides extract, as indicated. Control cells were not exposed to the ethanolic E ulmoides extract or estradiol. Estrogenic activity is expressed as fold increase in reporter gene activity compared to control. Data are mean ± SE of three replicates. 
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Supra-hormonal effect of E. ulmoides (EU) extract on androgen receptor and testosterone
Figure 8
Supra-hormonal effect of E. ulmoides (EU) extract on androgen receptor and testosterone. Testosterone-augmenting activity of a fixed dose of ethanolic EU extract (1c.f. = 50 ng/ ml treatment medium) with increasing doses of testosterone. Hela cells transiently expressing androgen receptor (AR) in the presence of AR-responsive luciferase reporter gene (Luc) were exposed to increasing doses of EU extract. Data are mean ± SE of three replicates. In-vivo testosterone and ventral prostate growth in prepubertal male WISTAR rats Figure 10 In-vivo testosterone and ventral prostate growth in prepubertal male WISTAR rats. The establishment of a dose response relationship between IM testosterone injections and ventral prostatic weight (as a measure of prostate development). Prepubertal male WISTAR rats were given IM testosterone injections of 500 µg, 2500 µg and 5000 µg. Control animals were given IM injections of vehicle (olive oil) only. Prostatic growth is expressed as the weight of the ventral prostate gland normalized to 100 g body weight of the individual rats. Each data point is mean ± SE of five animals' ventral prostate weights. 
Total 100
Caprylic acid, palmitic acid and stearic acid are polysaturated fatty acids (PFA). Palmitalic acid, Linoleic acid and Linolenic acid are omega-9, omega-6 and omega-3 polyunsaturated fatty acids (PUFA) respectively. These fatty acids share the general empirical formula C n H n O n . Caprylic acid was the major constituent with 78.2% abundance.
In-vivo testosterone-E. ulmoides (EU) extract and ventral prostate growth in prepubertal male WISTAR rats Figure 12 In-vivo testosterone-E. ulmoides (EU) extract and ventral prostate growth in prepubertal male WISTAR rats. The synergistic augmenting effect of E. ulmoides on testosterone mediated prostate growth. Prepubertal male WISTAR rats were given IM testosterone injections of 5000 µg (Lane 2). To test synergism between E. ulmoides and an androgen, experimental rats were given saturating IM testosterone injections of 5000 µg in conjunction with oral gavaging of 50 mg of E. ulmoides (EU) extract (Lane 3). Control animals were given IM injections of olive oil plus concurrent oral gavaging of ethanolic water. Prostatic growth is expressed as the weight of the ventral prostate gland normalized to 100 g body weight of the individual rats. Each data point is mean ± SE of five animals' ventral prostate weights. T r e a t m e n t Mean prostatic weight (mg/100g body weight) L a n e 1 .C o n t r o l L a n e 2 .T e s t o s t e r o n e a lo n e ( 5 0 0 0 u g ) L a n e 3 . T e s t o s t e r o n e ( 5 0 0 0 u g ) + Et h a n o lic EU e x t r a c t ( 5 0 m g d r y w e ig h t ) p-value <0.001
The 1 H NMR spectra of supra-hormonal fraction CB Figure 13 The 1 H NMR spectra of supra-hormonal fraction CB. Arrow a shows protons from water Effect of short-chain polysaturated fatty acids (PFAs) homologous series (C3 -C9) on androgen-dependent AR transactivational capacity Figure 14 Effect of short-chain polysaturated fatty acids (PFAs) homologous series (C3 -C9) on androgen-dependent AR transactivational capacity. The effect of short chain (C3 -C8) polysaturated fatty acids (PFAs) on androgen dependent AR transactivational capacity. Hela cells tranfected with AR expression plasmid were exposed to 10 µM of different PFAs as indicated, together with 1 nM DHT. C3 = propanoic acid (3:0). C4 = butanoic acid (4:0). C5 = pentanoic acid (5:0). C6 = n-caproic acid (6:0). C7 = heptanoic acid (7:0). C8 = caprylic acid (8:0). C9 = pelargonic acid (9:0). AR activity was measured with the multimeric AR reporter plasmid (ARE 2 -TATA-Luc) and luciferase activity in relative light units (RLU) was mean ± SE of 3 replicates. 
